课题基金 / 基金详情

Targeting thymic stromal lymphopoietin - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases

Targeting thymic stromal lymphopoietin - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases
靶向胸腺基质淋巴细胞生成素 - 用于治疗和预防特应性疾病的新型抗炎化合物
批准号：
449421
负责人：
Bhagat Vriti
金额：
$1.27万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-12-01 至 2021-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=449421&lang=en
关键词：
Atopic Diseases Drug Discovery And Development Inflammatory Skin Diseases New Anti-Inflammatory Drugs Topical Drug Delivery Tslp Inhibitors

项目摘要

项目成果

Bhagat Vriti的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The most common inflammatory skin disease worldwide is atopic dermatitis (AD) and up to 17% of Canadians are affected during their lifetime. AD impairs the quality of life as patients suffer from very dry skin, as well as social stigmatism. Additionally,
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying impairments in beta cell prohormone processing in diabetes
  • 批准号：
    474516
  • 项目类别：
    Studentship Programs
  • 资助金额：
    $10.93万
  • 财政年份：
    2022
  • 负责人：
    Bhagat Vriti
  • 依托单位：
    University of British Columbia
海外基金